Teva gets taste of its own antidepressant
Executive Summary
At least seven of the 16 firms with approvals for generic sertraline hydrochloride decide to launch their versions of Pfizer's antidepressant Zoloft after Teva's 180-day exclusivity expired Feb. 6. In January, Teva filed patent infringement lawsuits against multiple generic manufacturers, claiming the generics violate patents which relate to methods for manufacturing. According to IMS data, the generic substitution rate for Zoloft was 89 percent as of Dec. 15, with Teva controlling 45.4 percent of the generic share. The remaining portion went to Greenstone, Pfizer's authorized generics business...
You may also be interested in...
Execs On The Move: Repro-Med Replaces Its CEO
At Repro-Med, James Beck has been replaced by Linda Tharby as CEO, and more.
Start-Up Spotlight: Pre Diagnostics Picks Up Momentum In Early Neurodegenerative Disease Detection
Norway’s Pre Diagnostics uses the intracellular approach to neurodegenerative disease diagnosis. It believes its technology will open up a world of precision medicine for Alzheimer’s disease patients.
Coronavirus Notebook: New EMA Review To Contextualize Blood Clot Risk From AZ Jab, EU Gets Earlier Access To More Pfizer Vaccines
Denmark has stopped using the AstraZeneca vaccine completely, while the Canadian regulator is not recommending restrictions in any specific populations. Can a new EMA review provide better context to guide the vaccine’s use in different age groups and gender?